UK advertising regulator bans 5 Voy ads for at-home testosterone tests


The watchdog found that some ads overstated links between common symptoms and low testosterone and that a Facebook ad’s claim it affects 25% of men over 30 lacked evidence. Voy says it won’t run the ads again.
In its 18 November 2026 ruling, the UK Advertising Standards Authority banned 5 ads over misleading claims: 3 posters and 2 paid Facebook ads promoting at-home testosterone blood tests from Voy, an online healthcare provider. The decision followed August rulings that found misleading claims in testosterone-testing ads from BioID Health and Numan.
The watchdog said symptoms such as fatigue, irritability and low motivation can have many causes. It found that some Voy ads made those symptoms seem like stronger signs of low testosterone than they are on their own. It also found that one Facebook ad’s claim that low testosterone affects 25% of men over 30 was misleading because Voy’s evidence did not support it.
The rulings are part of a wider investigation into advertising aimed at men concerned about their health. In the August decisions, the watchdog said complaints and its Active Ad Monitoring system, which searches online for ads that might break the rules, helped identify ads for investigation.
The watchdog found BioID Health’s ads misleading because the company lacked evidence that its tests and services were more effective than those of NHS general practitioners. It also found the ads irresponsible because they implied those doctors were not thorough enough.
| Claim in the ad | Why the evidence fell short |
|---|---|
| 40% of men with obesity have low testosterone. | The figure came from a narrower group: men with obesity aged 45 or older who did not have diabetes. A separate analysis pooling several studies did not support the claim either. |

The White House withdrew the nomination a day before a US Senate panel was due to vote on 18 November on whether to send it to the full Senate, leaving the Food and Drug Administration without a permanent commissioner.
BioID Health said it meant to describe its specialist assessment, which combines a review of symptoms with blood testing, not to claim it was better than care from general practitioners. It acknowledged that it had no comparative clinical evidence. Numan argued that the US evidence it cited for the 40% figure was relevant to UK readers because both countries use the same threshold for defining obesity.
Voy said it withdrew the ads during the investigation and would not run them again, BBC Health reported.
Every patient decision at Voy is clinician-led and these campaigns were developed to align with UK advertising standards.
Chaudry said Voy regularly reviews its advertising to keep up with updated guidance. The watchdog said Voy and other providers can still advertise tests and services related to low testosterone, as long as their claims are accurate and backed by evidence.
3 min

The study includes waste incinerators and finds that much of the 2040 total could be avoided with existing technology. It estimates 33–68 million metric tons of CO₂ could still need balancing through carbon removal to reach net zero in 2050.
3 min

The 14–15 November hackathon spanned 593 events worldwide, with registrations up 59% from 2025, NASA says. Projects will be judged before global winners are announced in January.
2 min